Somatostatin PH&T lyophilized powder 3mg in vials for injections has obtained Marketing Authorisation in Vietnam and will be distributed by Duy Tan under the name Neostesin.

January 2011  PH&T and Duy Tan are proud to announce the successful registration of Neostesin in Vietnam.   Somatostatin (also known as growth hormone inhibiting hormone (GHIH) or somatotropin release-inhibiting factor (SRIF)) is a peptide hormone that regulates the endocrine system.  

Clinically somatostatin induces a splanchnic vasodilation that allows an efficient treatment of bleeding ulcers: thanks to its therapeutic profile, it is regarded as first-line intervention in gastro-intestinal haemorrhages. 

Vietnam’s pharmaceutical market is forecasted to top Asia-Pacific region’s growth at a Compound Annual Growth Rate of 19 percent in 2011 – 2013, said a recent survey conducted by an India-based market research and information analysis company.

The global crisis had a strong impact on Vietnam’s economy but, compared to other industries, pharmaceuticals weathered the storm quite well because demand tends to remain constant regardless of economic factors. Although consumption of medical services is much lower than other countries in the region, Vietnam’s pharmaceutical market has continued to grow over recent years and holds significant potential. With a population of more than 87 million, total expenditure on medicines increased from US$1.426 billion in 2008 to US$1.707 billion in 2009 and is forecast to reach US$2.05 billion in 2010.